These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15509119)

  • 41. Erythropoiesis stimulating agents: a personal journey.
    Leyland-Jones B
    J Natl Cancer Inst; 2013 Jul; 105(14):999-1001. PubMed ID: 23860202
    [No Abstract]   [Full Text] [Related]  

  • 42. Epoetin alfa and intravenous iron sucrose to treat severe anemia in a patient with chronic radiation enteropathy: a case report.
    Séronie-Vivien S; Mourey L; Tohfe M; Bugat R
    Med Oncol; 2003; 20(3):301-6. PubMed ID: 14514981
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anemia management with darbepoetin-alfa in outpatient hemodialysis patients switched from epoetin-alfa: a community hospital experience.
    Agrawal V; Mukherjee S; Kosuri R; Dumler F
    Am J Ther; 2010; 17(5):469-75. PubMed ID: 19770634
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation.
    Pizzi LT; Bunz TJ; Coyne DW; Goldfarb DS; Singh AK
    Kidney Int; 2008 Dec; 74(12):1588-95. PubMed ID: 19034302
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Regarding impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis.
    Tonelli M; Owen WF; Jindal K; Winkelmayer WC; Manns B
    Kidney Int; 2004 Oct; 66(4):1712; author reply 1712-3. PubMed ID: 15458473
    [No Abstract]   [Full Text] [Related]  

  • 47. National perspective on iron therapy as a clinical performance measure for maintenance hemodialysis patients.
    Owen WF; Szczech L; Johnson C; Frankenfield D
    Am J Kidney Dis; 1999 Oct; 34(4 Suppl 2):S5-S11. PubMed ID: 10516369
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia.
    Baldamus C; Krivoshiev S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A
    Adv Ther; 2008 Nov; 25(11):1215-28. PubMed ID: 18931828
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epoetin alfa therapy for anaemia in HIV-infected patients: impact on quality of life.
    Abrams DI; Steinhart C; Frascino R
    Int J STD AIDS; 2000 Oct; 11(10):659-65. PubMed ID: 11057937
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel aspects of vitamin C in epoetin response.
    Tarng DC
    J Chin Med Assoc; 2007 Sep; 70(9):357-60. PubMed ID: 17908648
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Frequency of anaemia and indications for treatment with epoetin in chronic renal failure at the pre-dialysis stage].
    Jungers PY; Nguyen-Khoa T; Joly D; Choukroun G; Massy ZA; Jungers P
    Presse Med; 2003 Feb; 32(5):212-6. PubMed ID: 12610461
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis.
    Thamer M; Zhang Y; Kaufman J; Cotter D; Dong F; Hernán MA
    JAMA; 2007 Apr; 297(15):1667-74. PubMed ID: 17440144
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Resource utilisation and time commitment associated with correction of anaemia in cancer patients using epoetin alfa.
    Lynch DM; Slaven T
    Clin Drug Investig; 2007; 27(9):661-2. PubMed ID: 17705574
    [No Abstract]   [Full Text] [Related]  

  • 54. Use of Carnitor for Epogen resistant anemia.
    Simard JC
    ANNA J; 1999 Feb; 26(1):41-2. PubMed ID: 10222857
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Epoetin alfa: recent strategies of use].
    Tumori; 1997; 83(6):975-8. PubMed ID: 9537918
    [No Abstract]   [Full Text] [Related]  

  • 56. Dose of epoetin alfa used in haemodialysis patients when switching from subcutaneous to intravenous administration.
    Pussell BA; Walker R
    Nephrology (Carlton); 2007 Apr; 12(2):120-5. PubMed ID: 17371332
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epoetin alfa improves quality of life in patients with cancer: results of metaanalysis.
    Jones M; Schenkel B; Just J; Fallowfield L
    Cancer; 2004 Oct; 101(8):1720-32. PubMed ID: 15386341
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management.
    Couture F; Turner AR; Melosky B; Xiu L; Plante RK; Lau CY; Quirt I
    Oncologist; 2005 Jan; 10(1):63-71. PubMed ID: 15632253
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Supporting epoetin alfa stimulated erythropoiesis: identifying appropriate iron levels: case study of the anemic patient.
    Sasak C
    Nephrol Nurs J; 2000 Dec; 27(6):612-5. PubMed ID: 16649342
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Standardized doses of epoetin alfa for hemodialysis patients.
    Nguyen TV; Iacovino LA
    Am J Health Syst Pharm; 2005 Sep; 62(18):1867. PubMed ID: 16141103
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.